Compare CPA & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPA | APGE |
|---|---|---|
| Founded | 1947 | 2022 |
| Country | Panama | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 4.7B |
| IPO Year | 2005 | 2023 |
| Metric | CPA | APGE |
|---|---|---|
| Price | $150.59 | $89.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 13 |
| Target Price | ★ $159.40 | $109.67 |
| AVG Volume (30 Days) | 315.6K | ★ 1.0M |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | ★ 6.09% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.51 | N/A |
| Revenue Next Year | $7.25 | N/A |
| P/E Ratio | $9.05 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $99.32 | $34.34 |
| 52 Week High | $156.41 | $95.32 |
| Indicator | CPA | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 66.99 | 58.46 |
| Support Level | $111.25 | $73.70 |
| Resistance Level | $156.41 | $93.61 |
| Average True Range (ATR) | 5.22 | 5.02 |
| MACD | 0.72 | 0.62 |
| Stochastic Oscillator | 92.13 | 89.73 |
Copa Holdings SA is a provider of airline passenger and cargo services through its subsidiaries. The company operates through the air transportation segment. It offers international air transportation for passengers, cargo, and mail, operating from its Panama City hub in the Republic of Panama, and domestic and international air transportation for passengers, cargo, and mail with a point-to-point route network through Copa Colombia, a Colombian air carrier. The company's geographical segments are North America, South America, Central America, and the Caribbean. It derives the maximum revenue from North America.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.